About Daniel Hume
Daniel Hume is a director at TG Therapeutics.
Form D filings name Daniel Hume as a director at Lirum Therapeutics.
Daniel Hume reports to the SEC as a director of 4 public companies, including Insight Digital Partners II (DYOR), National Holdings (NHLD) and Stemline Therapeutics (STML).
Daniel Hume first appears on SEC filings in 2015.
Experience
This experience comes from SEC filings. The years are when the filings name Daniel Hume in the role, so the role may have started earlier or lasted longer.
TI
TG Therapeutics, Inc.
Director
2015 – 2026 · Public company (TGTX)
II
Insight Digital Partners II
Director
2025 · Public company (DYOR)
NC
National Holdings Corp.
Director
2016 – 2021 · Public company (NHLD)
SI
Stemline Therapeutics Inc.
Director
2018 – 2020 · Public company (STML)
Key Colleagues at Startups
The people Daniel Hume works with at each company, as listed on that company's latest Form D.
Lirum Therapeutics, Inc. · Form D, Feb 23, 2023